Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
Presenter
Daniel M. Geynisman, MD
Fox Chase Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
General Session
Session Title
Innovations and Multidisciplinary Care in Early- and Late-Stage Urothelial Cancer
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02710734
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 438)
DOI
10.1200/JCO.2023.41.6_suppl.438
Abstract #
438
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 Genitourinary Cancers Symposium
A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.
Speaker: Daniel M. Geynisman, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).
Speaker: Hui Liu
Videos & Slides
2024 ASCO Annual Meeting
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.
Speaker: Andre Rashad Kydd, MD, PhD
Speaker: Panel Discussion